Haleon plc, the notable Sensodyne manufacturer, has witnessed significant traction in its
stock. Initially,
short interest increased by 40%, subsequently, the prominent entities
Van ECK Associates Corp,
Entropy Technologies LP,
WCM Investment Management and
Strategic Financial Concepts LLC boosted their stake in the company, acquiring numerous shares. However,
Pfizer gradually trimmed down the ownership, selling a $3 billion stake and 700M ordinary shares in a deal set to generate 2.66 billion pounds. Executives of Haleon have been active in share transactions as part of their
reward plan, reinforcing their strategic alignment to shareholder interests. The company also undertook a major
share buyback and set aside shares for staff plans. On technical analysis, Haleon is close to important technical resistance levels. Despite the potentially competitive landscape and occasional shortfalls in financial performance, brokerages recommend a
moderate buy. Guided by
BlackRock's move to increase its stake and the company's ambitious plans for an R&D center, institutional ownership of is interests were firmly held, reaching up to 77% of the company's share.
Haleon Stocks News Analytics from Mon, 18 Mar 2024 07:00:00 GMT to Sat, 15 Feb 2025 23:51:10 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor 1
